首页> 美国卫生研究院文献>Clinical and Diagnostic Laboratory Immunology >Profiling Antibodies to Mycobacterium tuberculosis by Multiplex Microbead Suspension Arrays for Serodiagnosis of Tuberculosis
【2h】

Profiling Antibodies to Mycobacterium tuberculosis by Multiplex Microbead Suspension Arrays for Serodiagnosis of Tuberculosis

机译:多重微珠悬浮阵列分析结核分枝杆菌的抗体用于结核病的血清学诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tuberculosis (TB) is a serious global disease. The fatality rate attributed to TB is among the highest of infectious diseases, with approximately 2 million deaths occurring per year worldwide. Identification of individuals infected with Mycobacterium tuberculosis and screening of their immediate contacts is crucial for controlling the spread of TB. Current methods for detection of M. tuberculosis infection are not efficient, in particular, for testing large numbers of samples. We report a novel and efficient multiplex microbead immunoassay (MMIA), based on Luminex technology, for profiling antibodies to M. tuberculosis. Microbead sets identifiable by unique fluorescence were individually coated with each of several M. tuberculosis antigens and tested in multiplex format for antibody detection in the experimental nonhuman primate model of TB. Certain M. tuberculosis antigens, e.g., ESAT-6, CFP-10, and HspX, were included to enhance the specificity of the MMIA, because these antigens are absent in nontuberculous mycobacteria and the vaccine strain Mycobacterium bovis bacillus Calmette-Guérin. The MMIA enabled simultaneous detection of multiple M. tuberculosis plasma antibodies in several cohorts of macaques representing different stages of infection and/or disease. Antibody profiles were defined in early and latent/chronic infection. These proof-of-concept findings demonstrate the potential clinical use of the MMIA. In addition, the MMIA serodetection system has a potential for mining M. tuberculosis open reading frames (about 4,000) to discover novel target proteins for the development of more-comprehensive TB serodiagnostic tests.
机译:结核病(TB)是一种严重的全球性疾病。结核病的致死率是传染病中最高的,全世界每年约有200万人死亡。鉴定感染结核分枝杆菌的个体并筛选其直接接触者对于控制结核病的传播至关重要。当前用于检测结核分枝杆菌感染的方法效率不高,特别是对于测试大量样品而言。我们报告了一种基于Luminex技术的新型高效多重微珠免疫测定(MMIA),用于分析结核分枝杆菌的抗体。可通过独特的荧光鉴定的微珠组分别用几种结核分枝杆菌抗原包被,并以多重形式进行测试以在实验性非人类灵长类TB模型中检测抗体。包括某些结核分枝杆菌抗原,例如ESAT-6,CFP-10和HspX,以增强MMIA的特异性,因为这些抗原在非结核分枝杆菌和疫苗菌株牛分枝杆菌Calmette-Guérin中不存在。 MMIA能够同时检测代表感染和/或疾病不同阶段的几只猕猴中的多种结核分枝杆菌血浆抗体。在早期和潜伏/慢性感染中定义了抗体谱。这些概念验证结果证明了MMIA的潜在临床应用。此外,MMIA血清检测系统具有挖掘结核分枝杆菌开放阅读框(约4,000个)的潜力,以发现新型靶蛋白,用于开发更全面的TB血清学诊断测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号